KCNK1抗体;KCNK1 Antibody—艾普蒂

+ +

•  

   

     HECTD2 Antibody (N-term)(Cat. #P32037) western blot analysis in human placenta tissue lysates (35ug/lane).This demonstrates the HECTD2 antibody detected the HECTD2 protein (arrow).    

  
  

**Background of KCNK1 Antibody**

KCNK1. also known as TWIK-1 (tandem pore domain weak inward rectifying K⁺ channel 1), is a member of the two-pore domain potassium (K2P) channel family. These channels regulate resting membrane potential and cellular excitability by facilitating passive potassium efflux. KCNK1 is widely expressed in various tissues, including the brain, kidneys, and heart, where it contributes to physiological processes such as ion homeostasis, neuroprotection, and cardiac rhythm modulation.

Antibodies targeting KCNK1 are essential tools for studying its expression, localization, and functional roles. They are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect KCNK1 protein levels in experimental models. Researchers utilize these antibodies to investigate KCNK1's involvement in diseases such as hypertension, neurological disorders, and cancer, where dysregulation of K⁺ channels may underlie pathological mechanisms.

Commercial KCNK1 antibodies are typically raised in hosts like rabbits or mice, often validated for specificity using knockout controls or siRNA-mediated silencing. Challenges include ensuring cross-reactivity across species (e.g., human, mouse, rat) and distinguishing KCNK1 from homologous K2P channels. Recent studies also explore KCNK1's potential as a therapeutic target, driving demand for reliable antibodies in drug discovery and mechanistic research. Proper validation and application-specific optimization remain critical for accurate experimental outcomes.